Table 1.

 The clinical characteristics of patients with GD and normal controls

Variable	Control group	Onset GD without 131I therapy	GD before 131I therapy	GD after 131I therapy	Normal range
No.	20	22	203
Age(y)	42.20±15.87	40.09±13.71	43.98±12.39
Gender(M/F)	11/9	3/19	31/172
FT3(pmol/L)	4.70±1.39	21.17±9.62	20.77±8.85	4.46±1.32	3.5-6.5
FT4(pmol/L)	14.69±4.44	64.48±44.15	56.77±34.57	15.27±7.47	11.5-22.7
TSH(mIU/L)	3.19±3.09	0.002±0.001	0.09±0.75	12.95±24.65	0.55-4.78
TRAb(IU/L)	0.65±0.48	11.28±10.17	16.95±12.47***	10.14±13.30	0-1.75
TPOAb(IU/mL)	29.44±4.30	644.90±625.50	839.35±567.10###	678.13±573.41	0-60

Data are expressed as mean±standard deviation according to the distribution

M male, F female, GD Graves’ disease

^***p < 0.001 represents TRAb levels of GD before ¹³¹I therapy versus GD after ¹³¹I therapy

^###p < 0.001 represents TPOAb levels of GD before ¹³¹I therapy versus GD after ¹³¹I therapy